Pfizer Launches Inlyta In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer announced Aug. 30 that it has launched tyrosine kinase inhibitor Inlyta (axinitib) in Japan for inoperable or metastatic renal cell carcinoma.